This company has been marked as potentially delisted and may not be actively trading. Audentes Therapeutics (BOLD) Institutional Ownership Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Audentes Therapeutics (NASDAQ:BOLD)Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$6.16MNumber ofInstitutional Sellers(last 12 months)0 Get BOLD Insider Trade Alerts Want to know when executives and insiders are buying or selling Audentes Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Audentes Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/12/2025Nuveen LLC3,958,413$5.98M0.0%N/A17.751% (Data available from 1/1/2016 forward) BOLD Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of BOLD shares? During the previous two years, the following institutional investors and hedge funds held shares of Audentes Therapeutics shares: Nuveen LLC ($5.98M).Learn more on BOLD's institutional investors. Which institutional investors have been buying Audentes Therapeutics stock? The following institutional investors have purchased Audentes Therapeutics stock in the last 24 months: Nuveen LLC ($3.96M). How much institutional buying is happening at Audentes Therapeutics? Institutional investors have bought a total of 3,958,413 shares in the last 24 months. This purchase volume represents approximately $6.16M in transactions. Related Companies Actuate Therapeutics Institutional Ownership Eledon Pharmaceuticals Institutional Ownership DiaMedica Therapeutics Institutional Ownership TuHURA Biosciences Institutional Ownership Phathom Pharmaceuticals Institutional Ownership Sol-Gel Technologies Institutional Ownership ProQR Therapeutics Institutional Ownership AC Immune Institutional Ownership Nanobiotix Institutional Ownership SELLAS Life Sciences Group Institutional Ownership This page (NASDAQ:BOLD) was last updated on 5/13/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Audentes Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Audentes Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
